Options
საკვერცხის კიბოს მკურნალობის ოპტიმიზაციისათვის: სიმსივნის მიკროსკოპული ავთვისებიანობისა და მაინფილტრირებელი T ლიმფოციტების კომპლექსური ანალიზი ციტორედუქციული ოპერაციების დროს.
Date Issued
2020
Author(s)
Advisor(s)
Institution
Faculty
Abstract
Ovarian cancer has a poor prognosis and high mortality among gynecological neoplasms.
It ranks 7th in cancer prevalence and 8th leading cause of death in the world.
The high mortality rate is due to the lack of effective screening methods and the slow
course of the disease. About 70-80% of ovarian cancers are diagnosed in advanced stages (III or
IV) of the disease, and the relapse rate is 75%, while the five-year disease-free survival is
observed in only 35%. patients.
Today, the complete cytoreduction of the tumor - debulking surgery - is considered to be
the best choice in the treatment of ovarian cancer(mainly stage III-IV) .
Establishing genetic risk factors for ovarian cancer and the molecular basis of oncogenesis
simultaneously with surgical treatment plays an important role in significantly improving
treatment outcomes and prognosis.
It is known that the degree of microscopic malignancy of cancer together with
histological types largely determines the prognosis of ovarian carcinoma. In addition, according
to recent data, the clinical outcome and prognosis of ovarian cancer are closely correlated with
the presence of tumor-infiltrating lymphocytes (TIL) in the tumor microenvironment.
The paper discusses 64 cases of ovarian cancer observed in 2016-2019. Patients underwent
cytoreductive surgeries. In the case of serous carcinomas, both the Shimizu/Silverberg and
“two-tier” systems were used to determine the degree of tumor differentiation; When using
Shimizu/Silverberg system, the degree of differentiation was additionally specified by
estimating of the oncoprotein p53 expression
It ranks 7th in cancer prevalence and 8th leading cause of death in the world.
The high mortality rate is due to the lack of effective screening methods and the slow
course of the disease. About 70-80% of ovarian cancers are diagnosed in advanced stages (III or
IV) of the disease, and the relapse rate is 75%, while the five-year disease-free survival is
observed in only 35%. patients.
Today, the complete cytoreduction of the tumor - debulking surgery - is considered to be
the best choice in the treatment of ovarian cancer(mainly stage III-IV) .
Establishing genetic risk factors for ovarian cancer and the molecular basis of oncogenesis
simultaneously with surgical treatment plays an important role in significantly improving
treatment outcomes and prognosis.
It is known that the degree of microscopic malignancy of cancer together with
histological types largely determines the prognosis of ovarian carcinoma. In addition, according
to recent data, the clinical outcome and prognosis of ovarian cancer are closely correlated with
the presence of tumor-infiltrating lymphocytes (TIL) in the tumor microenvironment.
The paper discusses 64 cases of ovarian cancer observed in 2016-2019. Patients underwent
cytoreductive surgeries. In the case of serous carcinomas, both the Shimizu/Silverberg and
“two-tier” systems were used to determine the degree of tumor differentiation; When using
Shimizu/Silverberg system, the degree of differentiation was additionally specified by
estimating of the oncoprotein p53 expression
File(s)
Loading...
Name
Sadoktoro Khachapuridze.pdf
Description
საკვერცხის კიბოს მკურნალობის ოპტიმიზაციისათვის: სიმსივნის მიკროსკოპული ავთვისებიანობისა და მაინფილტრირებელი Tლიმფოციტების კომპლექსური ანალიზი ციტორედუქციული ოპერაციების დროს.
Size
6.9 MB
Format
Adobe PDF
Checksum
(MD5):b6512136e3844ff87979825f44c5a4fe